Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | CCR1 | P32246 | 3/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | CCR8 | P51685 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197892 | 0.90 | GRM5 (0.60) | GRM5NOTUMSMN1; SMN2KDM4ETP53 | |
| SCHEMBL28474813 | 0.81 | ENPP3 (0.52) | GRM5NOTUMALOX15NPC1RAB9A | |
| SCHEMBL4194789 | 0.79 | KDM4E (0.61) | GRM5SMN1; SMN2KDM4ETP53CCR1 | |
| SCHEMBL28331391 | 0.78 | GRM5 (0.62) | GRM5SMN1; SMN2KDM4ETP53CCR1 | |
| SCHEMBL4179013 | 0.77 | GRM5 (0.49) | GRM5SMN1; SMN2KDM4ETP53CCR1 | |
| SCHEMBL4198173 | 0.77 | GRM5 (1.00) | GRM5SMN1; SMN2KDM4ETP53MAPK1 | |
| SCHEMBL28484910 | 0.77 | ENPP3 (0.47) | GRM5NOTUMKDM4ETP53ALOX15 | |
| SCHEMBL4182002 | 0.74 | GRM5 (0.63) | GRM5NOTUMSMN1; SMN2KDM4ETP53 | |
| SCHEMBL4189661 | 0.74 | GRM5 (0.43) | GRM5SMN1; SMN2KDM4ETP53CCR1 | |
| SCHEMBL4186479 | 0.74 | GRM5 (0.61) | GRM5SMN1; SMN2KDM4ETP53CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | claimed |
| EP-1210344-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2005-10-19 | — | — | EP | claimed |
| EP-1582519-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2005060961-A2 | TREATMENT OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRS) AND GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) | ASTRAZENECA AB (US) | 2005-07-07 | — | — | WO | claimed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | claimed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054491-A1 | Use | FABP6, SLC10A2, GPR119 | GRM5 582/4885NOTUM 96/4885SMN1; SMN2 2639/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885NOTUM 3543/4885SMN1; SMN2 1279/4885 |
| US-20070010553-A1 | New use | GRM5, GRM3, GRM1 | GRM5 1/4885NOTUM 1611/4885SMN1; SMN2 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.